Last updated: 07/17/2024 17:17:57

Follow-up study to investigate the effect of GSK2245035 on nasal allergic reactivity in subjects completing treatment in study TL7116958

Request patient level data
GSK study ID
204509
See study documents
Clinicaltrials.gov ID
NCT02446613
See results summary
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Overview
Eligibility
Locations
Study documents
Results summary
Plain language summaries
Additional information

Trial overview

Official title: A single-centre, follow-up study to investigate the effect of GSK2245035 on nasal allergic reactivity in subjects who completed treatment in study TL7116958 in 2014
Trial description: This study will evaluate the duration of effect of GSK2245035 on allergic reactivity by repeating a nasal allergen challenge (NAC) approximately one year after treatment in subjects from TL7116958. This is a single centre, single period study in subjects with respiratory allergy/allergies who completed the study TL7116958 in 2014 to investigate the long term effect of previous treatment with GSK2245035 compared with placebo on total nasal symptoms elicited by nasal allergen challenge. Subjects and staff will remain blinded to the treatment received in the TL7116958 study (GSK2245035 or placebo). The study will consist of a screening visit to assess eligibility criteria, a study period consisting of a single visit when the nasal allergen challenge will be performed, and follow up by phone or a clinic visit at the discretion of the investigator 4-7 days following the allergen challenge. Eligible subjects will participate in this study for approximately70 days total from screening to follow up.
Primary purpose:
Treatment
Trial design:
Single Group Assignment
Masking:
Single (Participant)
Allocation:
Not applicable
Primary outcomes:

Mean change from Baseline in the total nasal sym. score (TNSS) at post-NAC 15 minutes (min)

Timeframe: Day 1 (Baseline [pre-NAC] and post-NAC 15 min)

Mean change from Baseline in the TNSS over post-NAC 1 h

Timeframe: Day 1 (Baseline [pre-NAC], 15 to post-NAC 1h)

Mean change from Baseline in the TNSS over post-NAC 6 h

Timeframe: Day 1 (Baseline [pre-NAC] to post-NAC 6 h)

Maximum (max) mean change from Baseline (BL) in the TNSS over post-NAC 6 h

Timeframe: Day 1 (Baseline [pre-NAC] to post-NAC 6 h)

Percent change from baseline in the peak nasal inspiratory flow (PNIF) at post-NAC 15 min

Timeframe: Day 1 (Baseline [pre-NAC] and post-NAC 15 min)

Percent change from baseline in the PNIF over post-NAC 1 h

Timeframe: Day 1 (Baseline [pre-NAC] to post-NAC 1 h)

Percent change from baseline in the PNIF up to post-NAC 6 h

Timeframe: Day 1 (Baseline [pre-NAC] to post-NAC 6 h)

Maximum percent change from Baseline in PINF over post-NAC 6 h

Timeframe: Day 1 (Baseline [pre-NAC] to post-NAC 6 h)

Secondary outcomes:

Mean change from Baseline in individual nasal sym. including sneezing, nasal congestion, rhinorrhoea and nasal itch.

Timeframe: Day 1 (Baseline [pre-NAC] to post-NAC 6 h)

Interventions:
  • Other: Pollen allergen extract
    • Enrollment:
    16
    Primary completion date:
    2015-10-08
    Observational study model:
    Not applicable
    Time perspective:
    Not applicable
    Clinical publications:
    Ellis AK, Tsitoura DC, Quint D, Powley W, Lee LA. Safety and pharmacodynamics of intranasal GSK2245035, a TLR7 agonist for allergic rhinitis: a randomized trial. Clin Exp Allergy. 2017;47(9):1193-1203.
    Medical condition
    Asthma and Rhinitis
    Product
    GSK2245035
    Collaborators
    Not applicable
    Study date(s)
    June 2015 to August 2015
    Type
    Interventional
    Phase
    2

    Participation criteria

    Sex
    Female & Male
    Age
    18 - 65 years
    Accepts healthy volunteers
    No
    • Adult subjects with allergic rhinitis who completed study TL7116958 in 2014.
    • Healthy as determined by the investigator or medically qualified designee based on a brief physical examination.
    • Unresolved respiratory tract infection (RTI) at the time of study visit 2 NAC. Investigator discretion will be used regarding RTIs that have resolved during the 4 weeks preceding study visit 2.
    • Unresolved asthma exacerbation requiring hospitalization and/or treatment with oral steroids or high doses of inhaled steroids at the time of study visit 2 NAC.
    Inclusion and exclusion criteria
    Inclusion criteria:
    • Adult subjects with allergic rhinitis who completed study TL7116958 in 2014.
    • Healthy as determined by the investigator or medically qualified designee based on a brief physical examination.
    • Males and non-pregnant females.
    • Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the consent form and in this protocol.
    Exclusion criteria:
    • Unresolved respiratory tract infection (RTI) at the time of study visit 2 NAC. Investigator discretion will be used regarding RTIs that have resolved during the 4 weeks preceding study visit 2.
    • Unresolved asthma exacerbation requiring hospitalization and/or treatment with oral steroids or high doses of inhaled steroids at the time of study visit 2 NAC. Investigator discretion will be used regarding exacerbations that have resolved since screening visit.
    • A change in medical history since completion of the study TLR7116958 that in the opinion of the investigator and GlaxoSmithKline (GSK) medical monitor may pose additional risk factors.
    • Subjects with a history of treatment with allergen-specific immunotherapy since completion of the TL7116958 study; subjects that have taken an investigational drug that, in the opinion of the investigator or designee, would have an effect on the nasal allergen challenge
    • Subjects using steroid treatment (nasal steroids, 4 weeks; oral steroids, 4 weeks; inhaled steroids, 4 weeks) for allergic rhinitis and/or asthma prior to study visit 2, nasal allergen challenge
    • Subjects using antihistamines (nasal antihistamines, 48 hours; oral antihistamines 72 hours), decongestants (nasal decongestants, 24 hours; oral decongestants, 24 hours.), prior to study visit 2, nasal allergen challenge.
    • Subject is mentally or legally incapacitated.

    Trial location(s)

    Location
    Status
    Contact us
    Contact us
    Location
    GSK Investigational Site
    Kingston, Ontario, Canada, K7L 2V7
    Status
    Study Complete
    Contact us

    Study documents

    Clinical study report
    Available language(s): English
    Download document(s)
    Protocol
    Available language(s): English
    Download document(s)
    Scientific result summary
    Available language(s): English
    Download document(s)

    If you wish to request for full study report, please contact - [email protected]

    Results overview

    Results posted on ClinicalTrials.gov

    Recruitment status
    Study complete
    Actual primary completion date
    2015-10-08
    Actual study completion date
    2015-10-08

    Plain language summaries

    Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.

    Additional information about the trial

    Participate in clinical trial
    Additional information
    Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.
    Click here
    Access to clinical trial data by researchers
    Visit website